Proliferation Marker Inhibitors, also known as cell proliferation inhibitors, represent a distinct class of chemical compounds designed to interfere with the fundamental biological process of cell proliferation. Cell proliferation is a crucial mechanism in multicellular organisms, facilitating tissue growth, repair, and regeneration. In pathological conditions, however, uncontrolled cell proliferation can lead to the development of diseases like cancer. Proliferation Marker Inhibitors are primarily designed to target and regulate the activity of specific biomarkers or signaling pathways associated with cell division. By doing so, they aim to arrest or slow down the rate at which cells multiply, effectively impeding the progression of proliferative diseases.
These inhibitors often work by targeting key molecules involved in cell cycle regulation, DNA replication, or signal transduction pathways. They can interfere with various stages of the cell cycle, including G1, S, G2, and M phases, depending on their specific mechanism of action. Proliferation Marker Inhibitors may also exhibit selectivity towards cancer cells, exploiting the differences in proliferation markers between normal and malignant cells. By disrupting these markers or pathways, these inhibitors can halt the uncontrolled division of cancer cells, making them a potential tool in cancer research. Additionally, they hold promise in various other fields of biology and research, where precise control over cell proliferation is necessary to understand and manipulate biological processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is a tyrosine kinase inhibitor targeting EGFR (Epidermal Growth Factor Receptor), blocking downstream signaling pathways that promote cell proliferation. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib inhibits BCR-ABL kinase, disrupting the signaling cascade responsible for uncontrolled cell proliferation in chronic myeloid leukemia (CML). | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib inhibits CDK4/6, preventing phosphorylation of retinoblastoma protein (Rb) and halting cell cycle progression in estrogen receptor-positive breast cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases in the RAF/MEK/ERK pathway, as well as VEGFR and PDGFR, inhibiting angiogenesis and proliferation in various cancer types. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus inhibits mTOR (mammalian target of rapamycin), reducing protein synthesis and cell growth in tumors, particularly in renal cell carcinoma. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that blocks the downstream ERK signaling pathway, impairing cell proliferation in BRAF-mutated melanomas. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib selectively inhibits CDK4 and CDK6, leading to Rb protein hypophosphorylation and cell cycle arrest in estrogen receptor-positive breast cancer. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib inhibits JAK1 and JAK2, disrupting the JAK-STAT signaling pathway, reducing cell proliferation in myelofibrosis and polycythemia vera. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib inhibits BTK (Bruton's tyrosine kinase), suppressing B-cell signaling and proliferation, studied in the research of B-cell malignancies like CLL and MCL. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib targets multiple tyrosine kinases, including BCR-ABL and Src family kinases, disrupting signaling pathways that promote cell proliferation in leukemia. | ||||||